3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
27
Lymphoma, Non-Hodgkin
24
Leukemia, Lymphocytic, Chronic, B-Cell
24
Lymphoma, Mantle-Cell
23
Lymphoma, Follicular
17
Lymphoma, Large B-Cell, Diffuse
15
Multiple Myeloma
14
Recurrence
13
Hodgkin Disease
12
Lymphoma, B-Cell, Marginal Zone
7
Leukemia
7
Waldenstrom Macroglobulinemia
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
4
Neoplasms
4
Leukemia, B-Cell
4
Hematologic Neoplasms
4
Myeloproliferative Disorders
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, B-Cell
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphoid
3
Small Cell Lung Carcinoma
2
Leukemia, Biphenotypic, Acute
2
Burkitt Lymphoma
2
Sezary Syndrome
1
Sarcoma
1
Renal Insufficiency, Chronic
1
Interventions
pembrolizumab
45
Paclitaxel
8
Cisplatin
8
Carboplatin
8
lenvatinib
7
Pemetrexed
5
Gemcitabine
4
camrelizumab
3
Docetaxel
3
Capecitabine
3
epacadostat
2
avelumab
2
Fluorouracil
2
Cetuximab
2
Acetaminophen
2
vicriviroc
1
sinoporphyrin sodium
1
penpulimab
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
balstilimab
1
apatinib
1
Temozolomide
1
Tadalafil
1
Standard of Care
1
Serotonin 5-HT3 Receptor Antagonists
1
Radiotherapy
1
Radiosurgery
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Bendamustine Hydrochloride
×
Clear all
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled